Physician profile
Omar Daabies
NPI 1578179479
$45,975.75
in general payments reported to CMS, 2019-2025
28 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $871 · 2022: $1,311 · 2023: $1,606 · 2024: $4,978 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $13K · Travel and Lodging: $5,154 · Consulting Fee: $3,000 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,838.00 |
| Food and Beverage | $13,417.29 |
| Travel and Lodging | $5,154.28 |
| Consulting Fee | $3,000.00 |
| Education | $384.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $21,209.34 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Janssen Biotech, INC. | $8,361.21 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $5,490.65 | 2023-2025 | Zoryve |
| Abbvie INC. | $2,009.23 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,509.35 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,183.57 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $728.64 | 2021-2025 | |
| Lilly USA, LLC | $694.78 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $668.41 | 2021-2025 | |
| Ucb, INC. | $567.57 | 2021-2025 | Bimzelx |
| Amgen INC. | $518.09 | 2022-2025 | Otezla, Otezla |
| Botanix Sb INC | $452.21 | 2025 | Sofdra |
| Sun Pharmaceutical Industries INC. | $413.12 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Scientific Affairs, LLC | $342.70 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $295.70 | 2022-2025 | Sotyktu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $278.47 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $248.87 | 2022-2025 | |
| Leo Pharma INC. | $208.73 | 2022-2025 | Adbry, Spevigo |
| Incyte Corporation | $202.01 | 2025 | Opzelura |
| Epi Health, LLC | $138.83 | 2021-2022 | |
| Organon LLC | $132.72 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.46 | 2022-2024 | Spevigo |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Almirall LLC | $41.29 | 2025 | Seysara, Klisyri |
| Strata Skin Sciences, INC. | $36.69 | 2022-2025 | Xtrac |
| Cipher Pharmaceuticals US LLC | $24.27 | 2025 | Spinosad, Natroba |
| Biofrontera INC. | $20.41 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $19.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Daabies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.